1.
J Pediatric Infect Dis Soc
; 12(8): 477-480, 2023 Aug 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37466917
RESUMO
In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.
